Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a 2-Stage, Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) to ChAdOx1-S in adults aged 18 years and older.
Epistemonikos ID: 2c1a19014b2281564ec95bbdb5484fc4d60e29d3
First added on: Aug 18, 2021